Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois Sells 6,007 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $29.96, for a total value of $179,969.72. Following the completion of the transaction, the chief executive officer now owns 301,408 shares of the company’s stock, valued at approximately $9,030,183.68. The trade was a 1.95 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Cedric Francois also recently made the following trade(s):

• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Price Performance

APLS opened at $30.39 on Thursday. The stock has a fifty day moving average price of $31.95 and a 200 day moving average price of $33.25. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The stock has a market cap of $3.78 billion, a price-to-earnings ratio of -14.97 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same period in the prior year, the firm earned ($1.17) EPS. Apellis Pharmaceuticals’s quarterly revenue was up 78.3% on a year-over-year basis. Analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Institutional Trading of Apellis Pharmaceuticals

Large investors have recently modified their holdings of the company. Envestnet Asset Management Inc. increased its stake in shares of Apellis Pharmaceuticals by 42.2% in the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after purchasing an additional 39,931 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares during the last quarter. Profund Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 90.7% in the second quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after acquiring an additional 20,435 shares during the period. Algert Global LLC boosted its holdings in Apellis Pharmaceuticals by 137.8% in the 2nd quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after purchasing an additional 71,650 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter worth $1,370,000. 96.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on APLS shares. William Blair assumed coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an “outperform” rating for the company. Scotiabank decreased their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 6th. Needham & Company LLC reduced their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Finally, Robert W. Baird decreased their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).